Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

James Essell, MD, on how allogeneic transplantation is incorporated into hematologic malignancy

Dr. Essell explains how allogeneic transplantation is incorporated into hematologic malignancy today

Published: 18 December 2017

Recent Videos

video

Howard Hochster, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, discusses the ...

video

Kenneth Wang, MD, considers how staging esophageal cancer has changed and improved

Dr. Wang, Director of Advanced Endoscopy Group & Esophageal Neoplasia Clinic, Consultant, Division of Gastroenterology and Hematology, explains how staging ...

video

Khaldoun Almhanna, MD, MPH, on surveillance and the management of gastroesophageal cancer

Dr. Almhanna, Department of Gastrointestinal Oncology, Moffitt Cancer Center, Associate Professor of Oncology, University of South Florida College, describes how ...

video

Robert Soiffer, MD, discusses ways to enhance the activity of Il-2 in chronic GVHD

Dr. Soiffer discusses ways to enhance the activity of Il-2 in chronic graft versus host disease (GVHD)

video

Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML

Dr. Lane elaborates on the efficacy outcomes of SL-401 consolidation therapy in patients with acute myeloid leukemia (AML)

video

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of BLU-285 and what makes it unique

Dr. DeAngelo provides the mechanism of action of BLU-285 and explains what makes it unique and promising

video

Daniel J. DeAngelo, MD, PhD, on the phase 1 study of BLU-285 in advanced systemic mastocytosis

Dr. DeAngelo expands on the outcomes from the phase 1 study of BLU-285 in advanced systemic mastocytosis

video

Daniel J. DeAngelo, MD, PhD, offers his opinion on the clinical development of BLU-285

Dr. DeAngelo elaborates on the clinical development of BLU-285 moving forward

video

Jesus San-Miguel, MD, on the role of daratumumab in the front-line setting in multiple myeloma (MM)

Dr. San-Miguel discusses the role of daratumumab in the front-line setting in multiple myeloma (MM) patients

video

Ching-Hon Pui, MD, discusses minimal residual disease in pediatric and adult ALL patients

Dr. Pui elaborates on the optimal way to use minimal residual disease in pediatric and adult acute lymphocytic leukemia (ALL) ...

Related Videos

video-image

Khaldoun Almhanna, MD, MPH, on surveillance and the management of gastroesophageal cancer

video-image

Howard Hochster, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

video-image

Kenneth Wang, MD, considers how staging esophageal cancer has changed and improved

video-image

Robert Soiffer, MD, discusses ways to enhance the activity of Il-2 in chronic GVHD

video-image

Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML

video-image

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of BLU-285 and what makes it unique

video-image

Daniel J. DeAngelo, MD, PhD, on the phase 1 study of BLU-285 in advanced systemic mastocytosis

video-image

Daniel J. DeAngelo, MD, PhD, offers his opinion on the clinical development of BLU-285

video-image

Ching-Hon Pui, MD, discusses minimal residual disease in pediatric and adult ALL patients

video-image

Ching-Hon Pui, MD, on whether the FDA should accept minimal residual disease as a surrogate endpoint

video-image

Ching-Hon Pui, MD, explains how precision medicine is changing the way pediatric ALL is treated

video-image

Ching-Hon Pui, MD, speculates on the use of CAR T-cell therapy in pediatric ALL patients

video-image

Brad S. Kahl, MD, on the evidence for maintenance rituximab as a front-line treatment option in FLL

video-image

Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment

video-image

Jesus San-Miguel, MD, on the role of daratumumab in the front-line setting in multiple myeloma (MM)

video-image

Jens G. Lohr, MD, PhD, discusses the kind of information we can gather from liquid biopsy

video-image

Simon Rule, MD, discusses the ibrutinib data in relapsed/refractory MCL presented at ASH 2017

video-image

Jesus San-Miguel, MD, explains the efficacy and safety outcomes of the ALCYON clinical study

video-image

Simon Rule, MD, considers the clinical development plan with Imbruvica in mantle cell lymphoma (MCL)

video-image

Jesus San-Miguel, MD, on daratumumab in a first-line setting as a result of the ALCYON study